Mixed Dyslipidemia
Conditions
Brief summary
Subject incidence of treatment-emergent adverse events (TEAEs)
Detailed description
Change and percent change from baseline over time in fasting TG (triglyceride), Change and percent change from baseline over time in apolipoprotein (Apo)C-III, Change and percent change from baseline over time in fasting non-high-density lipoprotein cholesterol (non-HDL-C), Change and percent change from baseline over time in fasting HDL-C, Change and percent change from baseline over time in fasting total apolipoprotein B (ApoB), Change and percent change from baseline over time in fasting LDL-C (low-density lipoprotein cholesterol) using ultracentrifugation
Interventions
DRUGARO-APOC3
Sponsors
Arrowhead Pharmaceuticals Inc.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Subject incidence of treatment-emergent adverse events (TEAEs) | — |
Secondary
| Measure | Time frame |
|---|---|
| Change and percent change from baseline over time in fasting TG (triglyceride), Change and percent change from baseline over time in apolipoprotein (Apo)C-III, Change and percent change from baseline over time in fasting non-high-density lipoprotein cholesterol (non-HDL-C), Change and percent change from baseline over time in fasting HDL-C, Change and percent change from baseline over time in fasting total apolipoprotein B (ApoB), Change and percent change from baseline over time in fasting LDL-C (low-density lipoprotein cholesterol) using ultracentrifugation | — |
Countries
Hungary, Netherlands, Poland
Outcome results
None listed